Redhill Biopharma Ltd. (NASDAQ:RDHL) Sees Large Increase in Short Interest

Posted by Francis Steltz on Sep 26th, 2026

Redhill Biopharma Ltd. (NASDAQ:RDHL – Get Free Report) was the recipient of a large increase in short interest in September. As of September 15th, there was short interest totaling 235,258 shares, an increase of 2,710.1% from the August 31st total of 8,372 shares. Based on an average daily volume of 748,437 shares, the short-interest ratio is presently 0.3 days. Currently, 4.2% of the shares of the company are short sold.

Hedge Funds Weigh In On Redhill Biopharma

A hedge fund recently raised its stake in Redhill Biopharma stock. Gagnon Securities LLC increased its holdings in shares of Redhill Biopharma Ltd. (NASDAQ:RDHL – Free Report) by 383.1% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 86,102 shares of the biotechnology company’s stock after buying an additional 68,280 shares during the quarter. Gagnon Securities LLC owned 1.68% of Redhill Biopharma worth $89,000 at the end of the most recent reporting period. 7.20% of the stock is currently owned by institutional investors and hedge funds.

Redhill Biopharma Stock Down 3.9%

RDHL stock opened at $0.50 on Friday. Redhill Biopharma has a 52 week low of $0.50 and a 52 week high of $2.79. The business has a 50-day simple moving average of $0.64 and a 200 day simple moving average of $0.80. The company has a market cap of $3.04 million, a PE ratio of 0.00 and a beta of 4.96.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Redhill Biopharma in a research report on Monday, August 3rd. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has an average rating of “Sell”.

Get Our Latest Research Report on Redhill Biopharma

About Redhill Biopharma

(Get Free Report)

RedHill Biopharma Ltd. was a specialty biopharmaceutical company focused on developing and commercializing therapies for gastrointestinal diseases and certain infectious diseases. The company was founded in Israel and conducted operations primarily in the United States, where it pursued regulatory approval, commercialization and clinical development activities.

RedHill’s principal commercial product was Talicia, an oral combination of rifabutin, amoxicillin and omeprazole approved by the U.S.